Introduction {#S1}
============

Residual or recurrent laryngeal cancer after irradiation is a difficult clinical problem with a rate that ranges from 13% to 36% [@R01]^-^[@R04]. Although several treatment options exist for patients affected with laryngeal cancer at first presentation [@R05] [@R06], the options for those with recurrent cancer are limited based on the initial treatment received [@R07]. Cancers that recur after radiation therapy (RT) often exhibit aggressive behaviour, arise in a field in which lymphatic drainage is unpredictable and are associated with poor control rates [@R08]. Total laryngectomy is a frequently recommended option even for early recurrent cancers after chemoradiotherapy, but this procedure substantially impairs the quality of life primarily due to the permanent tracheostoma and the loss of the voice [@R09]. Supracricoid laryngectomies (SCLs) were recently classified by the European Laryngological Society [@R10] as Open Partial Horizontal Laryngectomies Type II, which include reconstructions either by cricohyoidoepiglottopexy (CHEP; renamed OPHL Type IIa) or cricohyoidopexy (CHP; renamed OPHL Type IIb). Both of these procedures provide reliable oncological and functional results for selected primary and recurrent patients with glottic and supraglottic carcinomas [@R11]^-^[@R14]. Several reports regarding the effectiveness of SCLs in terms of survival and functional results considering residual and recurrent cancer have been published.

The aim of this systematic review and meta-analysis was to evaluate the pooled oncological and short-term postoperative recovery outcomes of supracricoid laryngectomies with CHEP and CHP in the setting of recurrent laryngeal squamocellular cancer (SCC) after chemoradiotherapy.

Materials and methods {#S2}
=====================

Data sources and searches {#S2a}
-------------------------

We aimed to identify all papers that assessed the oncological and functional outcomes of patients treated with supracricoid laryngectomy for recurrence of SCC of the larynx after RT failure. The databases searched included MEDLINE, PubMed and EMBASE (from January 1990 to December 2015). We applied English language and abstract availability restrictions. Our search included the following keywords: laryngeal cancer, supracricoid laryngectomies, subtotal laryngectomy, cricohyoidopexy, cricohyoidoepiglottopexy, and/or retrospective study, prospective and randomised clinical study.

Selection of studies {#S2b}
--------------------

Publications were included if they included patients affected with recurrent laryngeal SCC after initial treatment with RT that was salvaged with supracricoid laryngectomy and reported the 5-year overall survival (OS), 5-year disease free survival (DFS) and short-term postoperative recovery outcomes.

We included only full published papers and excluded abstracts and reviews. Papers containing inadequately separable oncological or functional data, series that included patients treated with different procedures and those focusing on other topics or other surgical techniques were excluded.

Outcome measures {#S2c}
----------------

The primary outcome was 5-year overall survival (OS). The secondary outcomes were 5-year disease-free survival (DFS), short-term postoperative recovery outcomes and 5-year OS and 5-year DFS according to the T stage (early and locally advanced). Short-term postoperative recovery outcomes included the mean time until decannulation and the mean time required for oral feeding restoration, which is expressed as the mean time until nasogastric tube (NGT) or percutaneous endoscopic gastrostomy (PEG) removal. According to T stage, patients were divided into two groups for statistical analysis, i.e., early (rT1-T2) and locally advanced (rT3-T4) groups.

Data extraction {#S2d}
---------------

Initial selection was performed via the screening of the titles and abstracts by two pairs of independent reviewers (GR and CAL, PC and DT). For detailed evaluations, fulltext copies of all studies except one (Shenoy et al., 2000) that were possibly relevant were obtained. The data from each study were extracted independently by paired and independent reviewers (GR and CAL, PC and DT) using a pre-standardised data abstraction form. The data extracted from the publications were independently checked for accuracy by two additional reviewers (PC and PD). We resolved any possible disagreements by consensus in consultation with a third reviewer (CAL) when needed.

Quantitative analysis {#S2e}
---------------------

The meta-analysis was performed with a mixed random effect model using the DerSimonian and Laird method. The results were graphically represented using Forest plots. The proportions and 95% CIs for each outcome were separately calculated for each trial with the grouped data using the intention-to-treat principle. The choice to use the proportions was driven by the design of meta- analysis, which was based on the included studies. The tau^2^ was used to define the between-studies variance. The P value was set at 0.05. The homogeneity assumption was examined with the Q test with a degree of freedom (df) equal to the number of analysed studies minus 1. The heterogeneity was measured with the I^2^ statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance. The I^2^ was calculated from the basic results obtained from a typical meta-analysis as I^2^ = 100% Å \~ (Q -- df)/Q, where Q is Cochran\'s heterogeneity statistic, and df is the degrees of freedom. A value of 0% indicates no observed heterogeneity, and larger values indicate increasing heterogeneity. We performed an \"a priori\" sub-analysis of the oncological outcomes according to the early (rT1-T2) and locally advanced (rT3-T4) stages of recurrent laryngeal SCC. Next, we performed an \"a priori\" comparison of the same oncological outcomes between early (rT1-T2) and locally advanced (rT3-T4) stages of recurrent laryngeal SCC. For comparisons, we performed the meta-analyses with the odds ratios (ORs), and 2-sided p-values \< 0.05 were considered significant.

The analyses were conducted with OpenMetaAnalyst (version 6) and SPSS version 20 (IBM SPSS).

To evaluate potential publication bias, we used a weighted linear regression and a modified Macaskill\'s test, which provides more balanced type I error rates in the tail probability areas relative to other publication bias tests [@R15]. GR conducted the statistical analyses.

Limitations {#S2f}
-----------

This systematic review and meta-analysis has some limitations that need to be addressed. We included only full papers in the English language and excluded abstracts. Moreover, all of the included studies were retrospective. We observed substantial heterogeneity (I^2^ \> 50%) according to the Cochrane guidelines in 4 of 10 outcomes considered.

Results {#S3}
=======

Study selection {#S3a}
---------------

We identified 276 references. One hundred eight-seven papers were excluded after reading the titles, and 70 were excluded after reading the abstracts. We analysed 19 retrospective studies in full paper format because no prospective or randomised studies were found. Fourteen references including 291 patients fulfilled our search criteria [@R07] [@R09] [@R13] [@R16]^-^[@R18] [@R20]^-^[@R25] [@R27] [@R28]. Six of these studies involved mixed series [@R07] [@R09] [@R16] [@R17] [@R22] [@R23] because they included patients who underwent primary SCL and salvage SCL after RT failure. The remaining eight papers focused only on salvage surgeries. Five references were excluded, including 3 mixed series whose authors [@R12] [@R19] [@R29] reported only the cumulative data for the series, one paper [@R30] that was not available and one [@R26] study that included other surgical techniques. [Figure 1](#F1){ref-type="fig"} illustrates the study selection process.

![We identified 276 references. One hundred eight-seven papers were excluded after reading the title, and 70 were excluded after reading the abstracts. We analysed 19 retrospective studies in full paper format. Fourteen references including 291 patients fulfilled our search criteria. Five references were excluded, including 3 mixed series whose authors reported only the cumulative data of the series, one paper that was not available and one that included other surgical techniques.](0392-100X-36-439-g001){#F1}

Characteristics of studies included {#S3b}
-----------------------------------

The 14 papers included 291 adult patients. The 5-year OS and 5-year DFS were reported in all papers with the exceptions of Farrag et al. [@R22], Pellini et al. [@R23] and de Vincentiis [@R07]. For the papers of Sperry et al. [@R16], Nakayama et al. [@R17], Deganello et al. [@R20], Leon et al. [@R21] and Marchese-Ragona et al. [@R27], it was possible to extract these data from the text. All papers with the exceptions of Leone et al. [@R09] and Nakayama et al. [@R17] reported the short-term post-operative recovery outcomes, and Sperry et al. [@R16] and Pellini et al. [@R23] reported only the cumulative data for their series. The main characteristics of the studies included are reported in [Table I](#T1){ref-type="table"}.

###### 

Main characteristics of the included studies (R: retrospective, NA: not available, RT: radiotherapy, CHP: cricohyoidopexy, CHEP: cricohyoidoepiglottopexy, +A: arytenoidectomy, NGT: nasogastric tube, PEG: percutaneous endoscopic gastrostomy).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, Year      Study\   Surrtgery       Patients\   Age\         Sex\        Clinical\       Type of\      Follow-Up\   5-year\    5-year\    Decannulation\   NGT\
                    Type                     (n)         (mean,\      (male,\     Stage\          Surgery       Period\      Overall\   Disease\   in days          or PEG\
                                                         range)\      female)     after RT                      (mean,\      Survival   Free\                       removal\
                                                         in years                                               range)\                 Survival                    in days
                                                                                                                in months                                           
  ----------------- -------- --------------- ----------- ------------ ----------- --------------- ------------- ------------ ---------- ---------- ---------------- ------------
  De Vincentiis,\   R        RT and\         20          NA           NA          NA              NA            NA           NA         NA         38, 28-80        25, 20-39
  2015                       laser failure                                                                                                                          

  Leone, 2014       R        primary and\    4           60, 57-65    4 male      r T1b (1),\     CHP (3),\     41, 12-60    50%        50%        NA               NA
                             RT failure                                           rT2 (3)         CHEP (1)                                                          

  Sperry, 2013      R        primary and\    42          60, 34-79    37 male,\   rT1a (10),\     CHP or\       73, 0-207    95%        90.5%      NA               NA
                             RT failure                               5 female    rT1b (13),\     CHEP                                                              
                                                                                  rT2 (12),\                                                                        
                                                                                  rT3 (61),\                                                                        
                                                                                  rT4 (1)                                                                           

  Nakayama,\        R        primary and\    30          62           29 male,\   rpT1 (5),\      CHEP (30)     NA           81%        96.6%      NA               NA
  2013                       RT failure                               1 female    rpT2 (13),\                                                                       
                                                                                  rpT3 (9),\                                                                        
                                                                                  rpT4 (3)                                                                          

  Luna-Ortiz,\      R        RT failure      8           67, 43-87    6 male,\    rT1 (4),\       CHEP + A\     44, 20-67    50%        50%        16, 3-56         16, 3-60
  2009                                                                2 female    rT2 (4)         (3), CHEP\                                                        
                                                                                                  (5)                                                               

  Deganello,\       R        RT failure      31          60.1, 40-\   29 male,\   rT1a (1),\      CHEP 8,\      45, 6-180    60%        71%        27, 14-59        30, 12-72
  2008                                                   72           2 female    rT1b (5),\      CHP 23                                                            
                                                                                  rT2 (16),\                                                                        
                                                                                  rT3 (4),\                                                                         
                                                                                  rT3 (5)                                                                           

  Pellini, 2008     R        RT failure      78          59.6, 33-\   78 male     rT1a (6),\      CHEP + A\     70, 10-\     81.8%      95.5%      176.5, 12-365    15, 12-90
                                                         76                       rT1b (30),\     (33), CHEP\   300                                                 
                                                                                  rT2 (33),\      (29), CHP\                                                        
                                                                                  8 rT3, 1\       + A (8),\                                                         
                                                                                  rT4a            CHP (8)                                                           

  Leon, 2007        R        RT failure      9           54.4, 43-\   9 male      rT1a (5),\      CHEP (5),\    mean NA,\    78%        89%        11, 6-60         27, 16-40
                                                         67                       rT1b (2),\      CHEP + A\     4-120                                               
                                                                                  rT2 (1),\       (1), CHP\                                                         
                                                                                  rT2 (1)         (3)                                                               

  Farrag, 2007      R        primary and\    10          NA           NA          rT1 (1),\       NA            NA           NA         NA         52, 19-123       90, 30-\
                             RT failure                                           rT2 (7),\                                                                         210
                                                                                  rT3 (2)                                                                           

  Pellini, 2006     R        primary and\    17          NA           NA          r T1a (4),\     CHP           NA           NA         NA         21.7, 6-65       NA
                             RT failure                                           rT1b (3),\                                                                        
                                                                                  rT2 (8),\                                                                         
                                                                                  rT2 (1),\                                                                         
                                                                                  rT3 (1)                                                                           

  Sewnaik,\         R        RT failure      14          mean NA,\    12 male,\   rTis (1), T1\   CHEP 14       16, 3-41     92.8%      85.7%      176.5, 12-365    45, 10-\
  2006                                                   49-79        2 female    (6), T2 (7)                                                                       120

  Clark, 2005       R        RT failure      6           mean NA,\    NA          rT1a (2),\      CHEP (4),\    19, range\   72%        100%       9, 6-13          165, 60-\
                                                         51-64                    rT1b (1),\      CHP (2)       NA                                                  300
                                                                                  rT2 (3)                                                                           

  Marchese,\        R        RT failure      7           64, 55-72    7 male      rT2 (6),\       CHP (7)       122, 72-\    86%        86%        NA               42, 20-\
  2005                                                                            rT3 (1)                       173                                                 130

  Spriano,\         R        RT failure      15          65.2, 58-\   15 male     rT1a (4),\      CHEP (7),\    63.5, 36-\   80%        93.3%      21.7, 6-65       23.2, 12-\
  2002                                                   63                       rT1b (3),\      CHEP + A\     104                                                 48
                                                                                  rT2 (6),\       (4), CHP\                                                         
                                                                                  rT2 (1)         (3), CHP +\                                                       
                                                                                                  A (1)                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Definitions of oncological and functional outcomes {#S3c}
--------------------------------------------------

The oncological outcomes were calculated from the date of surgery. The endpoint for OS was the date of death regardless of cause, whereas the endpoint for DFS was date of recurrence (local, locoregional or metastatic). For the evaluations of short-term postoperative recovery, the outcomes included the mean time until decannulation and the mean time until NGT or PEG removal.

Primary outcome {#S3d}
---------------

The 5-year OS was 80.2% (CI 0.719-0.885; I^2^ = 62%; p = 0.003), and the corresponding Forest plot is shown in [Figure 2](#F2){ref-type="fig"}.

![Forrest plot of 5-year OS for patients treated with supracricoid laryngectomy after radiation therapy failure. Weights: Leone 2014: 2.5%, Sperry 2013 16.9%, Nakayama 2013: 12%, Luna-Ortiz 2009: 4.4%, Deganello 2008: 10.4%, Pellini 2008: 15.7%, Leon 2007: 6.2%, Sewanaik 2006: 12.5%, Clark 2005: 3.8%, Marchese 2005: 6.6%, Spriano 2002: 8.9%.](0392-100X-36-439-g002){#F2}

[Figure 3](#F3){ref-type="fig"} (upper box) shows the Forest plot for 5-year OS for T1-T2 (early stage according to TNM classification 31) patients (proportion: 0.798; CI 0.686-0.911; I2 = 35%; p = 0.167). The middle box shows the Forest plot for 5-year OS of T3-T4 patients (locally advanced stage; proportion: 0.923; CI 0.806-1.041; I^2^ = 0%; p = 0.697). The lower box depicts the Forest plot for 5-year OS for early *vs* locally advanced SCC patients (OR: 0.670; CI 0.117- 3.855; I^2^ = 7%; p = 0.340).

![Upper box: Forest plot of 5-year OS for patients affected with \"early\" T1-T2 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Leone 2014: 4.8%, Sperry 2013 37.3%, Deganello 2008: 20.1%, Clark 2005: 7.6%, Marchese 2005: 11.1%, Spriano 2002: 19.1%.Middle box: Forest plot of the 5-year OS for patients affected with \"locally advanced\" T3-T4 recurrent laryngeal cancer following radiation therapy RT failure who were treated with SCL. Weights: Sperry 2013 20.6%, Deganello 2008: 75.6%, Marchese 2005: 3.8%. Lower box: Forest plot of the 5-year OS for patients affected with \"early\" vs. \"locally advanced\" recurrent laryngeal cancer following radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 43.4%, Deganello 2008: 32%, Marchese 2005: 21.6%.](0392-100X-36-439-g003){#F3}

Secondary outcomes {#S3e}
------------------

The 5-year DFS was 89.5% (CI 0.838-0.952; I^2^ = 52%; p = 0.022) as illustrated in [Figure 4](#F4){ref-type="fig"}. [Figure 5](#F5){ref-type="fig"} (upper box) displays the Forest plot for the 5-year DFS of the T1-T2 patients (early stage; proportion: 0.869; CI 0.792-0.946; I^2^ = 15%; p = 0.315). The middle box presents the Forest plot for the 5-year DFS of the T3-T4 patients (locally advanced stage; proportion: 0.911; CI 0.784-1.037; I^2^ = 0%; p = 0.812). The lower box shows the Forest plot for the 5-year DFS of early vs. locally advanced stage patients (OR: 0.475; CI 0.093-2.430; I^2^ = 0%; p = 0.841).

![Forest plot of the 5-year DFS for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Leone 2014: 1.3%, Sperry 2013 15%, Nakayama 2013: 18.2%, Luna-Ortiz 2009: 2.4%, Deganello 2008: 8.3%, Pellini 2008: 20.8%, Leon 2007: 5.8%, Sewanaik 2006: 6.8%, Clark 2005: 6.5%, Marchese 2005: 4%, Spriano 2002: 10.9%.](0392-100X-36-439-g004){#F4}

![Upper box: Forest plot of the 5-year DFS for patients affected with \"early\" T1-T2 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Leone 2014: 2.4%, Sperry 2013 35.3%, Deganello 2008: 14.6%, Clark 2005: 14%, Marchese 2005: 6.2%, Spriano 2002: 27.4%. Middle box: Forest plot of the 5-year DFS for patients affected with \"locally advanced\" T3-T4 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 57.3%, Deganello 2008: 38.2%, Marchese 2005: 4.5%. Lower box: Forest plot of the 5-year DFS for patients affected with \"early\" vs. \"locally advanced\" recurrent laryngeal cancer following after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 29%, Deganello 2008: 51.3%, Marchese 2005: 19.7%.](0392-100X-36-439-g005){#F5}

The mean time until decannulation was 35.6 days (CI 24.3-46.9; I^2^ = 95%; p \< 0.001), and the corresponding Forest plot is presented in [Figure 6](#F6){ref-type="fig"}. The mean time until NGT or PEG removal was 28.3 days (CI 22.7-33.8; I^2^ = 86%; p \<= 0.001; [Fig. 7](#F7){ref-type="fig"}).

![Forest plot of the mean time until decannulation (days) for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Luna-Ortiz 2009: 6.5%, Deganello 2008: 12.2%, Pellini 2008: 8.2%, Leon 2007: 11.5%, Farrag 2007: 9.9%, Pellini 2006: 11.8%, Sewanaik 2006: 3.2%, Clark 2005: 12.3%, Spriano 2002: 11.8%, de Vincentiis 2015: 12%.](0392-100X-36-439-g006){#F6}

![Forest plot of the mean time until NGT or PEG removal (days) for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Luna-Ortiz 2009: 10.5%, Deganello 2008: 13.9%, Pellini 2008: 14.5%, Leon 2007: 14.7%, Farrag 2007: 3.1%, Sewanaik 2006: 7.6%, Clark 2005: 0.3%, Marchese 2005: 5%, Spriano 2002: 14.3%, de Vincentiis 2015: 15.5%.](0392-100X-36-439-g007){#F7}

Publication bias {#S3f}
----------------

No publication bias was detected according to Macaskill\'s modified test.

Discussion {#S4}
==========

In most centres in northern Europe and North America, radiotherapy is the primary treatment for patients with early laryngeal SCC [@R32]. RT is a well-established treatment for selected laryngeal carcinomas that elicits good oncologic and functional results. The reported failure rates range between 9-21% for T1 and 28-37% for T2 glottic carcinomas. In supraglottic laryngeal cancer, the reported failure rates for T1 and T2 lesions are 24-30% and 25%-45%, respectively [@R33]. Re-irradiation protocols (in combination with radio-sensitising agents) are at significant risk for morbidity [@R34] [@R35] and remain investigational; they may be considered for patients with unresectable locoregional disease. Therefore, surgery is the preferred modality for curative treatment of recurrent laryngeal cancer after failure of nonsurgical treatments. There are three options for salvage surgery after radiation failure: total laryngectomy, transoral laser microsurgery (TLM) and open partial laryngectomy.

Total laryngectomy is widely considered the classic approach to glottic SCC recurrence after irradiation 36, but considerably impairs the quality of life primarily due to the permanent tracheostoma and the loss of voice 9. Compared with alternative treatment options for laryngeal cancer, the oncological outcomes of TLM are inferior to those of open partial laryngectomy. TLM has a relatively lower mean larynx preservation rate of 72.3% *versus* 84% for open partial laryngectomy, which reflects a higher locoregional failure rate after TLM [@R08]. In the radio-recurrent setting, open partial laryngectomies have been less commonly used in the past due to concerns about unpredictable spreading and the postoperative function of the irradiated organ as well as a higher risk of complications [@R08]. The correct assessment of tumour extension of a recurrent laryngeal carcinoma may be difficult due to the residual inflammatory or functional changes associated with radiation therapy. Many recurrences present with multicentric tumour foci that are localised below intact mucosa and further masked by post-treatment oedema and fibrosis [@R37]. This pathological phenomenon that results in clinically significant difficulties in correctly restaging the tumour after irradiation justify the classical choice of salvage total laryngectomy in cases of carcinoma recurrence following radiotherapy failure [@R29]. There have been several reports about the effectiveness of open partial laryngectomies in terms of survival and functional results in residual or recurrent cancer.

To our knowledge, this is first systematic review and meta-analysis to examine the oncological outcomes according to T stage and short-term postoperative recovery outcomes of SCL for treatment of laryngeal SCC after RT failure.

This systematic review and meta-analysis resulted in the following findings: 1) 5-year OS was 80.2%; 2) 5-year DFS was 89.5%; 3) mean time until decannulation was 35.6 days; and 4) mean time until NGT or PEG removal was 28.3 days. The studies included in this meta-analysis share a common trait, i.e., the strict criteria for patient selection for candidacy for SCL after RT failure [@R09]. The indications and contraindications after the failure of RT are similar to those that have been specified for patients with previously untreated laryngeal tumours [@R30]. Therefore, we hypothesise that careful assessment of tumour extension might be responsible for the high 5-year OS and 5-year DFS.

In our sub-analysis, we found that 5-year OS for T1-T2 patients (early stage) was 79.8%; interestingly, this rate was 92.3% for T3-T4 patients (locally advanced stage). The 5-year DFS was 86.9% for T1-T2 patients and 91.1% for T3-T4 patients. These data might be attributable to inaccurate staging (i.e., understaging) prior to salvage surgery. In this regard, Zbaren et al. [@R37] reported that 52% of patients were clinically understaged and that the diagnostic accuracy of clinical evaluation (via fiberoptic laryngoscopy, CT, MRI, or microlaryngoscopic examination findings) was only 38%.

Nevertheless, our statistical analysis demonstrated that the differences between the 5-year OS and DFS of early and locally advanced SCC patients were not significantly different (p = 0.340 and p = 0.841, respectively). However, these results may have been influenced by the small size of the locally advanced stage group (only 17 patients).

Some of the papers included in this meta-analysis [@R09] [@R16] [@R23]^-^[@R25] [@R27] reported only clinical TNM. We strongly believe that future studies should also report pathological stage after salvage surgery.

The theoretical advantage of SCL over TL is that at least one functioning crico-arytenoid joint is maintained, and thus a permanent tracheostoma is not required, and the main laryngeal functions (i.e., respiration, phonation and swallowing) are preserved. Nevertheless, swallowing impairment represents the main functional issue due to the modification of the hypopharyngo/laryngeal anatomy. This condition has implications for the quality of life in addition to an association with potentially life threatening complications, such as aspiration pneumonia [@R38] [@R39].

This meta-analysis demonstrated that the mean time until NGT or PEG removal was 28.3 days, and the mean time until decannulation was 35.6 days. These data accord with the reports of other authors [@R40] [@R41] who prefer the initial removal of the NGT and initiation of oral alimentation with a tracheostomy tube to protect and clean the airways and permit the suction of any residual food that may be present [@R13]. However, the proper postoperative management of tracheostomies is still under debate. In contrast, different authors [@R28] [@R29] [@R42]^-^[@R56] have proposed early removal of the tracheostomy tube to ensure a rapid mobilisation of the residual larynx to avoid any interference with the cough reflex, which limits the incidence of pulmonary infection [@R13]. These different approaches might be due to personal experience or the preferences of the surgeon.

Some authors [@R27] [@R36] have suggested that, in consideration of the possibility of long-lasting swallowing disorders, clinicians should consider preoperative PEG in patients undergoing SCL as a salvage surgery for glottic carcinoma after irradiation failure. This suggestion is consistent with the opinion of the majority of the authors of the studies included in the present meta-analysis [@R13] [@R16] [@R18] [@R22] [@R25] [@R27] [@R28]. SCLs allow for satisfactory functional results, but surgical protocols need to be followed by adequate nursing and rehabilitation protocols. However, there is no evidence regarding when rehabilitation should be initiated, which criteria should be adopted to indicate the initiation and termination of rehabilitation, or which voice and swallowing rehabilitation procedures provide the optimal functional outcomes [@R57]. Therefore, we recommend that future work should focus on standardising postoperative care and rehabilitation protocols.

Conclusions {#S5}
===========

Recurrent laryngeal cancer after irradiation is a difficult clinical problem. Although total laryngectomy has been widely considered for many years to be the treatment of choice, this meta-analysis demonstrated that supracricoid laryngectomy for recurrent laryngeal cancer after chemoradiotherapy provides reliable oncological and short-term postoperative recovery outcomes.
